The estimated Net Worth of Brian Russell Wong is at least $3.37 Milione dollars as of 12 October 2020. Brian Wong owns over 20,000 units of RAPT Therapeutics stock worth over $650,410 and over the last 5 years he sold RAPT stock worth over $801,000. In addition, he makes $1,920,080 as President, Chief Executive Officer e Director at RAPT Therapeutics.
Brian has made over 3 trades of the RAPT Therapeutics stock since 2019, according to the Form 4 filled with the SEC. Most recently he sold 20,000 units of RAPT stock worth $801,000 on 12 October 2020.
The largest trade he's ever made was buying 25,000 units of RAPT Therapeutics stock on 4 November 2019 worth over $300,000. On average, Brian trades about 5,222 units every 38 days since 2019. As of 12 October 2020 he still owns at least 337,000 units of RAPT Therapeutics stock.
You can see the complete history of Brian Wong stock trades at the bottom of the page.
Dr. Brian Wong M.D. Ph.D. serves as President, Chief Executive Officer, Director of the Company. From January 2009 to August 2015, he served as Vice President of Immunology and Discovery Research and most recently as Senior Vice President, Research and Head of Immuno-Oncology at Five Prime Therapeutics, Inc., a biopharmaceutical company. From 2005 to 2009, he served as Director of Research in the Inflammation Disease Biology Area at F. Hoffmann-La Roche Ltd., a pharmaceutical company. Dr. Wong received an M.D. from Weill Cornell Medical College and a Ph.D. in Immunology from Rockefeller University. Dr. Wong obtained a B.A. in Chemistry and Biochemistry from Oberlin College. Wong’s extensive experience in the life sciences industry and his medical and scientific training provide him with the qualifications and skills to serve on our Board of Directors and as our President and Chief Executive Officer.
As the President, Chief Executive Officer e Director of RAPT Therapeutics, the total compensation of Brian Wong at RAPT Therapeutics is $1,920,080. There are 1 executives at RAPT Therapeutics getting paid more, with Rodney Young having the highest compensation of $2,296,220.
Brian Wong is 48, he's been the President, Chief Executive Officer e Director of RAPT Therapeutics since 2019. There are 14 older and no younger executives at RAPT Therapeutics. The oldest executive at RAPT Therapeutics, Inc. is Mary Gray, 67, who is the Independent Director.
Brian's mailing address filed with the SEC is C/O RAPT THERAPEUTICS, INC., 561 ECCLES AVENUE, SOUTH SAN FRANCISCO, CA, 94080.
Over the last 5 years, insiders at RAPT Therapeutics have traded over $79,325,123 worth of RAPT Therapeutics stock and bought 4,298,405 units worth $48,553,258 . The most active insiders traders include Peter Svennilson, David V Goeddel e Fund L.P.Topspin Biotech Fu.... On average, RAPT Therapeutics executives and independent directors trade stock every 11 days with the average trade being worth of $127,774. The most recent stock trade was executed by Dirk G. Brockstedt on 5 January 2024, trading 898 units of RAPT stock currently worth $20,456.
RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovering, developing, and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. Its lead oncology drug candidate is FLX475, an oral small molecule C-C motif chemokine receptor 4 antagonist that is in the Phase 1/2 clinical trial to investigate as a monotherapy and in combination with pembrolizumab in patients with advanced cancer. The company's lead inflammation drug candidate is RPT193 to selectively inhibit the migration of type 2 T helper cells into inflamed tissues. It is also pursuing a range of targets, including general control nonderepressible 2 and hematopoietic progenitor kinase 1 that are in the discovery stage of development. The company was formerly known as FLX Bio, Inc. and changed its name to RAPT Therapeutics, Inc. in May 2019. RAPT Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.
RAPT Therapeutics executives and other stock owners filed with the SEC include: